Keros Therapeutics (KROS) News Today $10.99 -0.02 (-0.18%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$11.00 +0.01 (+0.09%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Emerald Advisers LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Emerald Advisers LLC raised its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 57.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 244,633 shares of the company's stock afterMarch 25 at 5:44 AM | marketbeat.com29,146 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 29,146 shares of tMarch 23, 2025 | marketbeat.comKeros Therapeutics: Losing Its Lead Drug Is Bad MedicineMarch 13, 2025 | seekingalpha.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from AnalystsKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to theMarch 3, 2025 | marketbeat.comFY2026 EPS Estimate for Keros Therapeutics Lifted by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for Keros Therapeutics in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now anticipates that the comMarch 3, 2025 | marketbeat.comWhat is William Blair's Forecast for KROS Q1 Earnings?Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for shares of Keros Therapeutics in a research note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps forecasts that the comMarch 3, 2025 | marketbeat.comQ1 EPS Forecast for Keros Therapeutics Lifted by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Keros Therapeutics in a report released on Thursday, February 27th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($March 3, 2025 | marketbeat.comBank of America Securities Remains a Buy on Keros Therapeutics (KROS)March 2, 2025 | markets.businessinsider.comQ2 Earnings Estimate for KROS Issued By Leerink PartnrsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Keros Therapeutics in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith forecasts that the compMarch 1, 2025 | marketbeat.comKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesFebruary 28, 2025 | globenewswire.comWells Fargo & Company Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock PriceWells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday.February 28, 2025 | marketbeat.comHC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $40.00HC Wainwright dropped their price target on Keros Therapeutics from $47.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday.February 28, 2025 | marketbeat.comKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 28, 2025 | finanznachrichten.deWells Fargo Sticks to Their Buy Rating for Keros Therapeutics (KROS)February 27, 2025 | markets.businessinsider.comKeros Therapeutics (NASDAQ:KROS) Posts Quarterly Earnings Results, Beats Expectations By $0.22 EPSKeros Therapeutics (NASDAQ:KROS - Get Free Report) posted its earnings results on Wednesday. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.February 27, 2025 | marketbeat.comY Intercept Hong Kong Ltd Boosts Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Y Intercept Hong Kong Ltd raised its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,910.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,255 shares of the company's stock afteFebruary 27, 2025 | marketbeat.comTD Cowen Remains a Hold on Keros Therapeutics (KROS)February 26, 2025 | markets.businessinsider.comKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | globenewswire.comKeros Therapeutics (KROS) to Release Quarterly Earnings on WednesdayKeros Therapeutics (NASDAQ:KROS) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Short Interest UpdateKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 4,260,000 shares, an increase of 6.0% from the January 15th total of 4,020,000 shares. Based on an average trading volume of 1,500,000 shares, the days-to-cover ratio is currently 2.8 days.February 17, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSFebruary 11, 2025 | prnewswire.comLeerink Partnrs Has Bullish Outlook for KROS FY2028 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2028 earnings per share estimates for shares of Keros Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the cFebruary 10, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have received an average recommendation of "Moderate Buy" from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy ratingFebruary 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSFebruary 4, 2025 | prnewswire.comSG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)SG Americas Securities LLC bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,493 shares of the company's stock, valued at approximately $388,February 4, 2025 | marketbeat.comKeros Therapeutics to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSJanuary 28, 2025 | prnewswire.comAssenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Assenagon Asset Management S.A. trimmed its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 71.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,937 shares of theJanuary 25, 2025 | marketbeat.comKeros Therapeutics (KROS) Gets a Buy from ScotiabankJanuary 24, 2025 | markets.businessinsider.comKEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. ...January 24, 2025 | gurufocus.comKEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the FirmJanuary 24, 2025 | globenewswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)January 22, 2025 | tmcnet.comCantor Fitzgerald Predicts KROS FY2025 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Keros Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will earnJanuary 22, 2025 | marketbeat.comCantor Fitzgerald Downgrades Keros Therapeutics (KROS)January 22, 2025 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSJanuary 21, 2025 | prnewswire.comKeros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJanuary 21, 2025 | markets.businessinsider.comKeros spikes as Teva deal takes effect; Cantor downgrades on trial setbackJanuary 21, 2025 | msn.comKeros stock climbs on Takeda deal effectivenessJanuary 21, 2025 | in.investing.comKeros Therapeutics stock rating cut to Neutral, cites dosing setbackJanuary 21, 2025 | msn.comKeros Therapeutics (NASDAQ:KROS) Downgraded by Cantor Fitzgerald to NeutralCantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday.January 21, 2025 | marketbeat.comWedbush Downgrades Keros Therapeutics (KROS)January 18, 2025 | msn.comKeros Therapeutics Downgraded to ‘Hold’ Amid Strategic Shifts and Program RemovalJanuary 17, 2025 | markets.businessinsider.comKeros Therapeutics price target lowered to $15 from $40 at Piper SandlerJanuary 17, 2025 | markets.businessinsider.comPiper Sandler cuts Keros stock target to $15, keeps OverweightJanuary 17, 2025 | msn.comKeros Therapeutics (KROS) Gets a Buy from Piper SandlerJanuary 17, 2025 | markets.businessinsider.comPiper Sandler Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $15.00Piper Sandler dropped their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday.January 17, 2025 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by WedbushWedbush downgraded shares of Keros Therapeutics from an "outperform" rating to a "neutral" rating and set a $15.00 price objective for the company. in a research note on Friday.January 17, 2025 | marketbeat.comGuggenheim Reiterates "Neutral" Rating for Keros Therapeutics (NASDAQ:KROS)Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday.January 17, 2025 | marketbeat.comScotiabank Remains a Buy on Keros Therapeutics (KROS)January 17, 2025 | markets.businessinsider.comKeros Therapeutics (KROS) Receives a Buy from OppenheimerJanuary 17, 2025 | markets.businessinsider.com Remove Ads Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼1.570.78▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼34▲KROS Articles Average Week Remove Ads Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Disc Medicine News Agios Pharmaceuticals News Apogee Therapeutics News Mesoblast News Vera Therapeutics News Galapagos News Kiniksa Pharmaceuticals News Schrödinger News Ascentage Pharma Group International News IDEAYA Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
